Alzheimer's Disease Drug Trial Concludes Early Due to COVID-19 Concerns

The pharmaceutical industry has been moving fast to respond to the coronavirus pandemic -- but not all companies have been adjusting in the same ways.

For Axsome Therapeutics (NASDAQ: AXSM), adapting to COVID-19 has meant concluding patient participation early in the late-stage study of its lead drug candidate, AXS-05, in patients with Alzheimer's disease agitation. The changes to the study's protocols were made in compliance with new guidance from the Food and Drug Administration. 

But beyond the fact that it sped up the study, it also said the trial's top-line results, which had been expected in the third quarter, will be ready early in the second quarter.  

Continue reading

Source Fool.com